Reuters logo
BRIEF-Kitov enters immuno-oncology field through acquisition of Tyrnovo
January 12, 2017 / 7:30 PM / 10 months ago

BRIEF-Kitov enters immuno-oncology field through acquisition of Tyrnovo

Jan 12 (Reuters) - Kitov Pharmaceuticals Holdings Ltd

* Kitov enters immuno-oncology field through acquisition of Tyrnovo

* Kitov Pharmaceuticals says Will initially acquire an approximately 56% equity stake in tyrnovo from its majority shareholder

* Kitov Pharmaceuticals Holdings Ltd - will acquire for consideration of $2 million in cash and $1.8 million equivalent ordinary shares of Kitov

* Kitov Pharmaceuticals Holdings - upon closing of deal, co may buy additional equity stakes in Tyrnovo from all or part of co’s additional minority shareholders

* Kitov Pharmaceuticals - plans to file NDA with FDA for flagship combination drug, KIT-302 in Q1 2017 with commercial launch anticipated for H1 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below